New Treatment Option for Patients with HER2+ Gastroesophageal Junction Adenocarcinoma
The U.S. Food & Drug Administration has approved a new therapy for adult patients with locally advanced or metastatic HER2+ [...]
The U.S. Food & Drug Administration has approved a new therapy for adult patients with locally advanced or metastatic HER2+ [...]
The latest statistics released by the American Cancer Society projects that fewer Americans will die of Esophageal Cancer in 2021 [...]
These are challenging times. And we at ECAN are keeping our focus trained on the positive difference we can [...]
Despite the challenges of 2020, progress was achieved in the battle to end Esophageal Cancer - much of it thanks [...]
Findings of three studies important to Esophageal Cancer patients were presented at the 2020 ESMO (European Society of Medical Oncology) [...]
For the second year in a row, thousands of ECAN advocates made their voices heard and convinced lawmakers in the [...]
The U.S. Food and Drug Administration has approved Keytruda (Pembrolizumab) for treatment of advanced Esophageal Squamous Cell Carcinoma (ESCC). It [...]
The community of Athens, TN huddled together inside of the old building, the wood panels muffling their whispers and [...]
A team of UK researchers dug deep into the genomic roots of more than 550 cases of Esophageal Adenocarcinoma (EAC), [...]
ECAN's Medical Research Campaign What our Campaign Will Do: The United States Congress appropriated $90 million dollars this year for a [...]